CIK 0001649094 · Large accelerated filer
Vaxcyte, Inc.
Sign in to watch- Ticker
- PCVX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464233385
- Phone
- 650-837-0111
- Business address
- 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070
- Former names
- SutroVax, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,032,885
- in 7 filings, $3.7M under 10b5-1 plans
Net −$4,032,885. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-21 | GUGGENHIME ANDREW PRESIDENT AND CFO | Sale 10b5-1 | −683 | $87.70 | $60K | 109,491 |
| 2025-01-21 | GUGGENHIME ANDREW PRESIDENT AND CFO | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 254,827 | ||
| 2025-01-15 | Loxam Teri Director | Option exercise 10b5-1 | +6,250 | $22.70 | $142K | 13,425 |
| 2025-01-15 | Loxam Teri Director | Sale 10b5-1 | −146 | $80.46 | $12K | 13,279 |
| 2025-01-15 | Loxam Teri Director | Sale 10b5-1 | −215 | $81.53 | $18K | 13,064 |
| 2025-01-15 | Loxam Teri Director | Sale 10b5-1 | −1,136 | $82.89 | $94K | 11,928 |
| 2025-01-15 | Loxam Teri Director | Sale 10b5-1 | −1,202 | $83.93 | $101K | 10,726 |
| 2025-01-15 | Loxam Teri Director | Sale 10b5-1 | −1,043 | $85.29 | $89K | 9,683 |
| 2025-01-15 | Loxam Teri Director | Sale 10b5-1 | −966 | $86.26 | $83K | 8,717 |
| 2025-01-15 | Loxam Teri Director | Sale 10b5-1 | −1,013 | $87.38 | $89K | 7,704 |
| 2025-01-15 | Loxam Teri Director | Sale 10b5-1 | −529 | $88.54 | $47K | 7,175 |
| 2025-01-15 | Loxam Teri Director | Option exercise · Stock Option (right to buy) 10b5-1 | −6,250 | 6,250 | ||
| 2025-01-06 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Option exercise 10b5-1 | +5,000 | $21.41 | $107K | 33,222 |
| 2025-01-06 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −954 | $84.86 | $81K | 32,268 |
| 2025-01-06 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −3,921 | $85.73 | $336K | 28,347 |
| 2025-01-06 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Sale 10b5-1 | −125 | $86.52 | $11K | 28,222 |
| 2025-01-06 | Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 154,497 | ||
| 2025-01-02 | Wassil Jim CHIEF OPERATING OFFICER | Option exercise 10b5-1 | +8,000 | $2.42 | $19K | 213,695 |
| 2025-01-02 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −1,356 | $82.88 | $112K | 212,339 |
| 2025-01-02 | Wassil Jim CHIEF OPERATING OFFICER | Sale 10b5-1 | −5,483 | $83.69 | $459K | 206,856 |
Page 14 of 16 · 319 trades